US Patent Issued to Bristol-Myers Squibb on Jan. 27 for "Serum albumin-binding fibronectin type III domains" (Massachusetts, Wisconsin, New Jersey Inventors)

ALEXANDRIA, Va., Jan. 28 -- United States Patent no. 12,534,511, issued on Jan. 27, was assigned to Bristol-Myers Squibb Co. (Princeton, N.J.).

"Serum albumin-binding fibronectin type III domains" was invented by Tracy S. Mitchell (Andover, Mass.), Michael L. Gosselin (Boston), Dasa Lipovsek (Pepperell, Mass.), Rex Parker (Titusville, N.J.), Ray Camphausen (Wayland, Mass.), Jonathan H. Davis (Madison, Wis.) and David Fabrizio (South Hamilton, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules...